Doral, FL, Feb. 08, 2018 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC PINK: ETST) (“ETST" or the “Company"), an innovative biotech company focused on the cannabinoid (CBD), nutraceutical and pharmaceutical fields, as well as on R&D for certain medical devices, today announced launch date for the Company’s highly-anticipated, revamped industrial hemp Cannabidiol (CBD) products, which lead to forecast updates reflecting to a record-high monthly revenue.
February 13, 2018 is the official launch date for the Company’s highly anticipated High Grade Full Spectrum Cannabinoids product, and corresponding marketing strategy, announced early December 2017.
High Grade Full Spectrum Cannabinoids is composed of European CO2, supercritical extracted, organically grown, and unfiltered industrial hemp. The Company was originally planning on using American industrial hemp but was able to secure a reliable high-quality source in Europe to continue offering European industrial hemp, which led to slight delays from the original launch time frame. ETST will be one of the first companies to market its industrial hemp product as a Cannabinoid Complex instead of CBD, disclosing the milligrams (mg) of each Cannabinoid (CBD, CBDV, CBG, CBC, CBN, & CBDA). Cannabinoid complex is naturally occurring in the industrial hemp plant used, and is rich in Terpenes, and Saponins. Mixed, bottled, and packaged in the U.S. at a CGMP facility, the Company’s High Grade Full Spectrum Cannabinoids offer the highest therapeutic quality that current end-users trust and carry forward. Preorders are currently being accepted online.
Since last year’s announcement on product and marketing strategy revamp, Mr. Checkout distributor launched last week, and new veteran Chef Sales Officer, (CSO), the exponential demand increase has led the Company to revise forecasts to reflect what is anticipated to be the highest revenue month to date. The Company has new chain stores, clinics, and health shops eagerly waiting for the official launch to place their initial orders.
Nickolas S. Tabraue, ETST’s president, director and COO concludes, “Between appointing a new Chief Sales Officer, launching revamped industrial hemp products with fresh branding and marketing strategies, and our new distributor Mr. Checkout, we are on track for a record-setting revenue month. We've made clear that we intend to make 2018 our breakout year, and we are laying a strong foundation in this first quarter. We will continue to provide updates on our material events as we can.”
“While much of the up-listing and Reg A+ offering processes are out of our hands, we want to reassure our shareholders that we have worked hard to prepare the required paperwork for our audit and offering filings. We are prioritizing transparency and creating lasting value for our stakeholders and are committed to up-listing to the QB tier of the OTC Markets this year. We will provide updates as progress is made.”
About Earth Science Tech, Inc. (ETST): Earth Science Tech has among the highest quality, purity and full-spectrum high-grade hemp CBD (cannabidiol) oil on the market. Made using the superior supercritical CO2 liquid extraction, ETST’s CBD oil is 100% natural and organic. The company’s research, performed alongside the University of Central Oklahoma and DV Biologics laboratory, demonstrates that ETST is the top nutritional and dietary supplement brand for high-grade hemp CBD oil.
To learn more and to buy CBD Hemp Oil, please visit: www.EarthScienceTech.com
About Earth Science Pharmaceutical: Earth Science Pharmaceutical, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Earth Science Pharmaceutical is focused on becoming a world leader in the development of low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for STIs (sexually transmitted infections and/or diseases). Earth Science Pharmaceutical CEO Dr. Michel Aubé, a renowned scientist, is committed to help grow ETST in the medical and pharmaceutical industry.
To learn more please visit: www.EarthSciencePharmaceutical.com
About Cannabis Therapeutics: Cannabis Therapeutics, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc. (ETST). Cannabis Therapeutics was formed as an emerging biotechnology company poised to become a world leader in cannabinoid research and development for a broad line of cannabis cannabinoid-based pharmaceuticals, nutraceuticals, as well as other products & solutions. Cannabis Therapeutics’ mission it to help change the health care landscape by introducing its proprietary cannabis-cannabinoid-based products made for both the pharmaceutical and retail consumer markets worldwide.
To learn more please visit: www.CannabisThera.com
About KannaBidioiD: KannaBidioid, Inc. is wholly owned subsidiary of Earth Science Tech, Inc. (ETST). KannaBidioid is focused in the recreational space to manufacture and distribute vapes/e-liquids and gummy edibles in the recreational space formulated by its unique Kanna and CBD formula. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhance focus, and help with nicotine addiction based on their properties.
To learn more please visit: www.KannaBidioiDInc.com
SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.